TriPath Imaging Inc and its wholly owned subsidiary, TriPath Oncology Inc have achieved a key milestone in the collaboration with BD (Becton, Dickinson and Company) and Millennium Pharmaceuticals Inc.

TriPath Imaging has installed its proprietary interactive system to aid in the development and support of the genomics-based marker discovery program at Millennium's research laboratory in Cambridge, Massachusetts. This prototype system is built on TriPath Imaging's extended SlideWizard modular platform and integrates the Company's telepathology workstation with tools to aid in image relocation and quantification. The system will accelerate molecular marker development by allowing the remote exchange of images and other data utilized in the evaluation process.

Paul R. Sohmer, Chairman, President and CEO of TriPath Imaging, stated, "Achievement of this critical milestone reflects the progress we have made since announcing the creation of TriPath Oncology. This is a key step in our development of molecular diagnostics and pharmacogenomic tests for cancer. We anticipate that the modular system installed at Millennium will serve as the platform upon which we will develop and commercialize our first tissue and cell-based molecular tests for malignant melanoma, and cancer of the prostate, breast, ovary and cervix."

TriPath Imaging develops, manufactures and markets products to improve cancer detection, diagnosis, staging and treatment selection. In July 2001, TriPath Imaging was selected by BD, to develop and commercialize molecular diagnostics and pharmacogenomic tests for malignant melanoma and cancer of the prostate, breast, ovary and cervix as part of the ongoing strategic alliance of BD and Millennium. TriPath Imaging will manage its activities for this development and commercialization effort through TriPath Oncology.